Skip to main content
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. — Investor Relations & Filings

Ticker · MCRB ISIN · US81750R2013 LEI · 549300GMXBE5NUWISF13 US Manufacturing
Filings indexed 666 across all filing types
Latest filing 2025-09-30 Director's Dealing
Country US United States of America
Listing US MCRB

About Seres Therapeutics, Inc.

https://www.serestherapeutics.com/

Seres Therapeutics, Inc. is a commercial-stage biotechnology company developing microbiome-based therapeutics. The company's platform creates a novel class of biological drugs, known as live biotherapeutics, which consist of rationally selected consortia of live bacteria. These therapies are designed to modulate the functional properties of the gastrointestinal microbiome to treat and prevent diseases. Seres' development programs target medically vulnerable patient populations, with a focus on preventing bacterial bloodstream and antimicrobial-resistant (AMR) infections, as well as treating gastrointestinal-related immune diseases.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2025-09-30 English
4
Director's Dealing
2025-08-19 English
4
Director's Dealing
2025-08-19 English
4
Director's Dealing
2025-08-19 English
4
Director's Dealing
2025-08-19 English
4
Director's Dealing
2025-08-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.